Preventive healthcare startup AllizHealth secures $350K from Mumbai Angels, others

Pune-based preventive healthcare startup AllizHealth, which identifies a patient’s health risks through their health records, has secured $350,000 (Rs 2 crore) in funding from Mumbai Angels and a few other individual investors.

Aniruddha Malpani (medical director at Malpani Infertility Clinic), Hetal Sonpal (head, strategic alliances at Intel Corporation), Kishore Ganji (founder-CEO of Astir IT Solutions), entrepreneur-turned-serial investor Sanjay Mehta and Prashant Choksey (founder & CEO of Choksey Constructions and co-founder of Mumbai Angels) are among those who participated in this round of funding.

“We are thrilled with this round of funding from Mumbai Angels and consider it as a validation of our ideas and vision,” said Chinmoy Mishra, co-founder, AllizHealth. It plans to use the funds to expand operations and strengthen the technology platform.

The startup has built a repository of health information to predict health trends. It has also launched a web-based tool to record existing medical conditions, allergies, medications, prescriptions, surgeries, reports and clinical diagnosis.

The company claims to have already served about 100,000 adults through tie-up with some of India’s leading Insurance and Hospital providers and corporates. In addition, it has served over 9,000 students from 25 schools across Pune, Bangalore and Delhi.

AllizHealth, operates primarily in a B2B model and competes with other startups in the healthcare space such as Practo, Millman and Healthcaremagic.

Bootstrapped in 2013, the firm was founded by Mishra with a seed capital of Rs 15 lakh, which was largely spent on building the platform. An NIT Rourkela graduate, Mishra also holds an MBA from Babson College, Boston.

Prior to founding the startup, he had worked with a US-based technology and health insurance company Aetna. Mishra returned to India in 2008 and was associated with another healthcare venture before starting AllizHealth.

Leave Your Comment(s)